Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2018 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference

BURLINGTON, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf,...
February 02, 2018 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BURLINGTON, Mass., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to six new employees for an aggregate of 38,800...
January 08, 2018 07:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)

Data show that 95% of patients achieved clinical benefit after a single administration of ZILRETTATo date, 90% of eligible patients received a second administration between Weeks 12 and 24 ...
December 18, 2017 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Enrolls First Patient in Study Evaluating the Pharmacokinetics and Safety of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) in Osteoarthritis of the Shoulder and Hip

BURLINGTON, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has enrolled the first patient in a clinical trial to evaluate the...
December 13, 2017 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee

Acquisition complements existing portfolio with an innovative, locally administered therapeutic intended to provide persistent effective concentrations of IL-1Ra in the knee for at least a yearNew...
December 11, 2017 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer

BURLINGTON, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Scott Kelley, M.D., has been named Chief Medical Officer. Dr. Kelley previously...
December 07, 2017 16:35 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) in Bilateral Osteoarthritis of the Knee

BURLINGTON, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the enrollment of the first patient in a clinical trial to evaluate the pharmacokinetics...
December 06, 2017 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

BURLINGTON, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf,...
December 04, 2017 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BURLINGTON, Mass., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to three new employees for an aggregate of 20,500...
November 28, 2017 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

BURLINGTON, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf,...